Taurine and liver diseases: a focus on the heterogeneous protective properties of taurine
- 966 Downloads
Taurine (2-aminoethylsulfonic acid) has many physiological and pharmacological functions in most tissues. It is abundantly maintained in the liver by both endogenous biosynthesis and exogenous transport, but is decreased in liver diseases. In the hepatic lobule, there are heterogeneous differences in metabolism between the pericentral (PC) and periportal regions, and the distributions of the biosynthesis capacity and specific taurine transporter expression are predominantly in the PC region. In cases of depletion of hepatic taurine level, serious liver damages were observed in the PC region. Taurine has protective effects against xenobiotics-induced liver damages in the PC region, but not xenobiotics-induced PP region damages. The xenobiotics that injure the PC region are mainly catabolized by NADPH-dependent cytochrome P450 2E1 that is also predominantly expressed in the PC region. Taurine treatment seems to be a useful agent for CYP2E1-related liver diseases with predominant damages in the PC region.
KeywordsCYP2E1 Hepatic lobule Oxidative stress PC region Xenobiotics
We thank Taisho Pharmaceutical Co., LTD. (Tokyo, Japan) for an educational grant to our taurine research. We are also grateful for the expert advises from the late Dr. Bernard Bouscarel who was associate professor in the Department of Biochemistry and Molecular Biology of the George Washington University, Washington DC, USA.
Conflict of interest
The authors declare that they have no conflict of interest.
- Gentile CL, Nivala AM, Gonzales JC, Pfaffenbach KT, Wang D, Wei Y, Jiang H, Orlicky DJ, Petersen DR, Pagliassotti MJ, Maclean KN (2011) Experimental evidence for therapeutic potential of taurine in the treatment of non-alcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol 301(6):R1710–R1722PubMedGoogle Scholar
- Han X, Patters AB, Jones DP, Zelikovic I, Chesney RW (2006) The taurine transporter: mechanisms of regulation. Acta Physiol (Oxf) 187:61–73Google Scholar
- Ikeda S, Tachikawa M, Akanuma SI, Fujinawa J, Hosoya KI (2012) Involvement of gamma-aminobutyric acid transporter 2 in the hepatic uptake of taurine in rats. Am J Physiol Gastrointest Liver Physiol 303:G291–G297Google Scholar
- Kato J, Ido A, Hasuike S, Uto H, Hori T, Hayashi K, Murakami S, Terano A, Tsubouchi H (2004) Transforming growth factor-beta-induced stimulation of formation of collagen fiber network and anti-fibrotic effect of taurine in an in vitro model of hepatic fibrosis. Hepatol Res 30:34–41PubMedGoogle Scholar
- Kiernan F (1833) The anatomy and physiology of the liver. Trans R Soc Lond 123:711–770Google Scholar
- Ogasawara M, Nakamura T, Koyama I, Nemoto M, Yoshida T (1993) Reactivity of taurine with aldehydes and its physiological role. Chem Pharm Bull (Tokyo) 41:2172–2175Google Scholar
- Pasantes MH, Wright CE, Gaull GE (1985) Taurine protection of lymphoblastoid cells from iron-ascorbate induced damage. Biochem Pharmacol 34:2205–2207Google Scholar
- Warskulat U, Flogel U, Jacoby C, Hartwig HG, Thewissen M, Merx MW, Molojavyi A, Heller-Stilb B, Schrader J, Haussinger D (2004) Taurine transporter knockout depletes muscle taurine levels and results in severe skeletal muscle impairment but leaves cardiac function uncompromised. FASEB J 18:577–579PubMedGoogle Scholar
- Warskulat U, Borsch E, Reinehr R, Heller-Stilb B, Monnighoff I, Buchczyk D, Donner M, Flogel U, Kappert G, Soboll S, Beer S, Pfeffer K, Marschall HU, Gabrielsen M, Amiry-Moghaddam M, Ottersen OP, Dienes HP, Haussinger D (2006) Chronic liver disease is triggered by taurine transporter knockout in the mouse. FASEB J 20:574–576PubMedGoogle Scholar
- Waterfield CJ, Turton JA, Scales MD, Timbrell JA (1993) Reduction of liver taurine in rats by beta-alanine treatment increases carbon tetrachloride toxicity. Toxicology 29:7–20Google Scholar
- Wu G, Yang J, Sun C, Luan X, Shi J, Hu J (2009) Effect of taurine on alcoholic liver disease in rats. Amino Acids 643:313–322Google Scholar